OLMA
NASDAQ · Biotechnology
Olema Pharmaceuticals Inc
$7.34
+0.58 (+8.58%)
Open$6.85
Previous Close$6.76
Day High$7.36
Day Low$6.74
52W High$36.26
52W Low$6.24
Volume—
Avg Volume1.46M
Market Cap641.36M
P/E Ratio—
EPS$-2.12
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+129.0% upside
Current
$7.34
$7.34
Target
$16.81
$16.81
$15.48
$16.81 avg
$21.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |
| Rev Growth | +22.4% | +21.1% | -4.4% |
| Debt/Equity | 0.25 | 0.24 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |